For bispecific T-cell engagers (TCEs) in solid tumors, translating from preclinical to clinical exposures results in inconsistent predictions and dose discrepancies of up to 3 orders of magnitude. Using in vitro or mouse trimer per target cell translation results in predictions closer to the pharmacologically active dose.
Access this resource
